Literature DB >> 27769864

HMGB1 induces human non-small cell lung cancer cell motility by activating integrin αvβ3/FAK through TLR4/NF-κB signaling pathway.

Jianhua Zhu1, Jing Luo2, Yongchao Li3, Min Jia4, Yueqin Wang4, Yan Huang4, Shuhong Ke5.   

Abstract

High mobility group box 1 (HMGB1) is a ubiquitous nuclear protein with multi-functions and plays an important role in tumorigenesis and metastasis in various human cancers. In the present study, we found that HMGB1 induced migration of in human non-small cell lung cancer (NSCLC) cells by up-regulating integrin αvβ3 expression. Further investigation evidenced that HMGB1 activated Toll-like receptor 4 (TLR4) and NF-κB, which was responsible for αvβ3 up-regulation. Furthermore, HMGB1-induced integrin αvβ3 expression led to focal adhesion kinase (FAK) phosphorylation and increased paxillin and talin mRNA expression. Knockdown HMGB1 inhibited xenograft tumor metastasis in athymic mice. Taken together, our findings suggested that HMGB1 enhances tumor cell migration ability by activating αvβ3/FAK through TLR4/NF-κB signaling, leading to metastasis of NSCLC.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FAK; HMGB1; Migration; NSCLC; TLR4; αvβ3

Mesh:

Substances:

Year:  2016        PMID: 27769864     DOI: 10.1016/j.bbrc.2016.10.052

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  S100A9 promotes prostate cancer cell invasion by activating TLR4/NF-κB/integrin β1/FAK signaling.

Authors:  Zhonghua Lv; Wenlin Li; Xichao Wei
Journal:  Onco Targets Ther       Date:  2020-07-03       Impact factor: 4.147

Review 2.  The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.

Authors:  Lei Wu; Lili Yang
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

3.  High Mobility Group Box 1 Protein in Osteoarthritic Knee Tissue and Chondrogenic Progenitor Cells: An Ex Vivo and In Vitro Study.

Authors:  Gunar Wagner; Christoph Lehmann; Christa Bode; Nicolai Miosge; Andrea Schubert
Journal:  Cartilage       Date:  2019-03-26       Impact factor: 4.634

4.  Roles of toll-like receptors: From inflammation to lung cancer progression.

Authors:  Jinjing Gu; Yi Liu; Bin Xie; Pingping Ye; Jiefan Huang; Zhe Lu
Journal:  Biomed Rep       Date:  2017-12-28

5.  14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.

Authors:  Jing Luo; Jian-Feng Yao; Xiao-Fei Deng; Xiao-Dan Zheng; Min Jia; Yue-Qin Wang; Yan Huang; Jian-Hua Zhu
Journal:  J Exp Clin Cancer Res       Date:  2018-02-09

6.  Galectin-3 activates TLR4/NF-κB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression.

Authors:  Wu Zhou; Xing Chen; Qinghua Hu; Xuliang Chen; Yingji Chen; Lingjin Huang
Journal:  BMC Cancer       Date:  2018-05-22       Impact factor: 4.430

7.  Overexpression of miR-758 inhibited proliferation, migration, invasion, and promoted apoptosis of non-small cell lung cancer cells by negatively regulating HMGB.

Authors:  Guo-Hua Zhou; Yi-Yu Lu; Jing-Lian Xie; Zi-Kun Gao; Xiao-Bo Wu; Wei-Shen Yao; Wei-Guang Gu
Journal:  Biosci Rep       Date:  2019-01-18       Impact factor: 3.840

Review 8.  Immune targets in the tumor microenvironment treated by radiotherapy.

Authors:  Omer M Ozpiskin; Lu Zhang; Jian Jian Li
Journal:  Theranostics       Date:  2019-01-30       Impact factor: 11.556

9.  The TLR4/ERK/PD‑L1 axis may contribute to NSCLC initiation.

Authors:  Xiuhua Kang; Penghui Li; Chuibin Zhang; Yunshan Zhao; Huoli Hu; Guilan Wen
Journal:  Int J Oncol       Date:  2020-05-19       Impact factor: 5.650

10.  Recombined humanized endostatin-induced suppression of HMGB1 expression inhibits proliferation of NSCLC cancer cells.

Authors:  Fan-Jie Meng; Shuo Wang; Yi-Jie Yan; Chun-Yang Wang; Zhi-Yu Guan; Jun Zhang
Journal:  Thorac Cancer       Date:  2018-11-28       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.